Results 1 to 10 of about 69,832 (232)

Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model [PDF]

open access: bronze, 2014
X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency that results from mutations within the gene encoding Bruton’s tyrosine kinase (BTK). Many XLA-associated mutations affect splicing of BTK pre-mRNA and severely impair B cell development ...
Behlke, Mark A   +20 more
core   +3 more sources

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma [PDF]

open access: goldBiomarker Research, 2022
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang   +3 more
doaj   +2 more sources

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders [PDF]

open access: yesBiomolecules
BTK (Bruton’s tyrosine kinase) has become a key therapeutic target across several hematologic diseases, beginning with its original use in CLL/SLL.
Andrea Duminuco   +9 more
doaj   +2 more sources

Inhibition of bruton’s tyrosine kinase directly alleviates pathogenic CD4+ T cell response via PPAR-γ signaling in autoimmune uveitis [PDF]

open access: yesJournal of Neuroinflammation
Background Bruton’s tyrosine kinase (BTK), a key regulator of immune responses, has been extensively studied in B cells and innate immunocytes. Small-molecule BTK inhibitors (BTKi) have shown remarkable efficacy in multiple preclinical and clinical ...
Zhiqiang Xiao   +13 more
doaj   +2 more sources

SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation

open access: yesCancer Biology & Medicine, 2022
Objective: B-cell antigen receptor (BCR) signaling is required to maintain the physiological functions of normal B cells and plays an important pathogenic role in B-cell malignancies. Bruton tyrosine kinase (BTK), a critical mediator of BCR signaling, is
Liao Wang   +7 more
doaj   +1 more source

Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases

open access: yesPlatelets, 2021
Antiplatelet medications comprise the cornerstone of treatment for diseases that involve arterial thrombosis, including acute coronary syndromes (ACS), stroke and peripheral arterial disease.
Maan H. Harbi   +4 more
doaj   +1 more source

Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2022
Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Tony Eight Lin   +10 more
doaj   +1 more source

Megjegyzések a lokális Craig interpolációhoz

open access: yesElpis, 2022

Zalán Molnár, Övge Öztürk
doaj   +1 more source

Egyetemi hallgatók környezettudatossága a materializmus, az élettel való elégedettség, a politikai, illetve a pandémiával kapcsolatos nézeteik függvényében

open access: yesMetszetek, 2022
Az elmúlt évtizedekben egyre nagyobb figyelmet kap a környezeti problémák és az ezzel ös - szefüggő társadalmi jelenségek vizsgálata. Az egyetemi hallgatók környezettudatosságának és környezettudatosságukat befolyásoló tényezőknek a megismerése ...
Ferenc Mónus   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy